Skip to main content
PMC home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;95(7):588–591. doi: 10.1111/j.1349-7006.2004.tb02491.x

Frequent promoter methylation and gene silencing of CDH13 in pancreatic cancer

Mitsuru Sakai 1, Kenji Hibi 1, Katsumi Koshikawa 1,✉, Soichiro Inoue 1, Shin Takeda 1, Tetsuya Kaneko 1, Akimasa Nakao 1
PMCID: PMC11159011  PMID: 15245595

Abstract

It has recently been reported that CDH13 expression is silenced by aberrant methylation of the promoter region in several cancers. We examined the methylation status of the CDH13 gene in pancreatic cancer using methylation‐specific PCR (MSP), and detected aberrant methylation of CDH13 in all 6 pancreatic cancer cell lines examined. To confirm the status of the CDH13 gene in relation to the methylation pattern, we next examined CDH13 expression in these cell lines using reverse transcription (RT)‐PCR. As expected, no CDH13 expression was detected in any of the 6 pancreatic cancer cell lines. Moreover, 5‐aza‐2′‐deoxycytidine (5‐aza‐dC) treatment of CDH13‐methylated cell lines led to restoration of CDH13 expression. Among primary pancreatic cancers, 19 of 33 (58%) cases exhibited CDH13 methylation, while no cases exhibited it in corresponding normal pancreatic tissues. CDH13 methylation was detected even in relatively early pancreatic cancers, such as stage II cancers and cancers less than 2 cm in diameter. Our results suggest that the aberrant methylation of CDH13 occurs frequently in pancreatic cancer, even at a relatively early stage.

References

  • 1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23–47. [DOI] [PubMed] [Google Scholar]
  • 2. Rosewicz S, Wiedenmann B. Pancreatic carcinoma. Lancet 1997; 349: 485–9. [DOI] [PubMed] [Google Scholar]
  • 3. Schneider G, Schmid RM. Genetic alterations in pancreatic carcinoma. Mol Cancer 2003; 2: 15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL, Bos JL. K‐ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant‐enriched polymerase chain reaction analysis and allele‐specific oligonucleotide hybridization. Am J Pathol 1993; 143: 545–54. [PMC free article] [PubMed] [Google Scholar]
  • 5. Kalthoff H, Schmiegel W, Roeder C, Kasche D, Schmidt A, Lauer G, Thiele HG, Honold G, Pantel K, Riethmuller G. p53 and K‐RAS alterations in pancreatic epithelial cell lesions. Oncogene 1993; 8: 289–98. [PubMed] [Google Scholar]
  • 6. Wilentz RE, Geradts J, Maynard R, Offerhaus GJ, Kang M, Goggins M, Yeo CJ, Kern SE, Hruban RH. Inactivation of the p16 (INK4A) tumor‐suppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res 1998; 58: 4740–4. [PubMed] [Google Scholar]
  • 7. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350–3. [DOI] [PubMed] [Google Scholar]
  • 8. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991; 251: 1451–5. [DOI] [PubMed] [Google Scholar]
  • 9. Levenberg S, Yarden A, Kam Z, Geiger B. p27 is involved in N‐cadherin‐mediated contact inhibition of cell growth and S‐phase entry. Oncogene 1999; 18: 869–76. [DOI] [PubMed] [Google Scholar]
  • 10. Takeichi M. Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol 1993; 5: 806–11. [DOI] [PubMed] [Google Scholar]
  • 11. Behrens J. The role of cell adhesion molecules in cancer invasion and metastasis. Breast Cancer Res Treat 1993; 24: 175–84. [DOI] [PubMed] [Google Scholar]
  • 12. Lee SW. H‐Cadherin, a novel cadherin with growth inhibitory functions and diminished expression in human breast cancer. Nat Med 1996; 2: 776–82. [DOI] [PubMed] [Google Scholar]
  • 13. Toyooka KO, Toyooka S, Virmani AK, Sathyanarayana UG, Euhus DM, Gilcrease M, Minna JD, Gazdar AF. Loss of expression and aberrant methylation of the CDH13 (H‐cadherin) gene in breast and lung carcinomas. Cancer Res 2001; 61: 4556–60. [PubMed] [Google Scholar]
  • 14. Toyooka S, Toyooka KO, Harada K, Miyajima K, Makarla P, Sathyanarayana UG, Yin J, Sato F, Shivapurkar N, Meltzer SJ, Gazdar AF. Aberrant methylation of the CDH13 (H‐cadherin) promoter region in colorectal cancers and adenomas. Cancer Res 2002; 62: 3382–6. [PubMed] [Google Scholar]
  • 15. Kawakami M, Staub J, Cliby W, Hartmann L, Smith DI, Shridhar V. Involvement of H‐cadherin (CDH13) on 16q in the region of frequent deletion in ovarian cancer. Int J Oncol 1999; 15: 715–20. [DOI] [PubMed] [Google Scholar]
  • 16. Roman‐Gomez J, Castillejo JA, Jimenez A, Cervantes F, Boque C, Hermosin L, Leon A, Granena A, Colomer D, Heiniger A, Torres A. Cadherin‐13, a mediator of calcium‐dependent cell‐cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa. J Clin Oncol 2003; 21: 1472–9. [DOI] [PubMed] [Google Scholar]
  • 17. Hibi K, Robinson CR, Booker S, Wu L, Hamilton SR, Sidransky D, Jen J. Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Res 1998; 58: 1405–7. [PubMed] [Google Scholar]
  • 18. Hibi K, Taguchi M, Nakayama H, Takase T, Kasai Y, Ito K, Akiyama S, Nakao A. Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. Clin Cancer Res 2001; 7: 3135–8. [PubMed] [Google Scholar]
  • 19. Sato M, Mori Y, Sakurada A, Fujimura S, Horii A. The H‐cadherin (CDH13) gene is inactivated in human lung cancer. Hum Genet 1998; 103: 96–101. [DOI] [PubMed] [Google Scholar]
  • 20. Hibi K, Takahashi T, Sekido Y, Ueda R, Hida T, Ariyoshi Y, Takagi H, Takahashi T. Coexpression of the stem cell factor and the c‐kit genes in small‐cell lung cancer. Oncogene 1991; 6: 2291–6. [PubMed] [Google Scholar]
  • 21. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995; 1: 686–92. [DOI] [PubMed] [Google Scholar]
  • 22. Dammann R, Schagdarsurengin U, Liu L, Otto N, Gimm O, Dralle H, Boehm BO, Pfeifer GP, Hoang‐Vu C. Frequent RASSF1A promoter hypermethylation and K‐ras mutations in pancreatic carcinoma. Oncogene 2003; 22: 3806–12. [DOI] [PubMed] [Google Scholar]
  • 23. Fukushima N, Sato N, Ueki T, Rosty C, Walter KM, Wilentz RE, Yeo CJ, Hruban RH, Goggins M. Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am. J Pathol 2002; 160: 1573–81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Fukushima N, Sato N, Sahin F, Su GH, Hruban RH, Goggins M. Aberrant methylation of suppressor of cytokine signalling‐1 (SOCS‐1) gene in pancreatic ductal neoplasms. Br J Cancer 2003; 89: 338–43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP, Hruban RH, Goggins M. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 2000; 60: 1835–9. [PubMed] [Google Scholar]
  • 26. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E‐cadherin in the transition from adenoma to carcinoma. Nature 1998; 392: 190–3. [DOI] [PubMed] [Google Scholar]
  • 27. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation‐specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Nakayama H, Hibi K, Takase T, Yamazaki T, Kasai Y, Ito K, Akiyama S, Nakao A. Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients. Int J Cancer 2003; 105: 491–3. [DOI] [PubMed] [Google Scholar]
  • 29. Klump B, Hsieh CJ, Nehls O, Dette S, Holzmann K, Kiesslich R, Jung M, Sinn U, Ortner M, Porschen R, Gregor M. Methylation status of p14ARF and p16INK4a as detected in pancreatic secretions. Br J Cancer 2003; 88: 217–22. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES